Shingles Vaccine May Reduce Cardiovascular Disease Risk by 9%

Clinical effectiveness against circulating variants relies on strict adherence to cold-chain stability protocols.** In evaluating Shingles Vaccine May Reduce Cardiovascular Disease Risk by 9%, FDA authorization data confirms that updated seasonal formulations generate robust neutralizing antibody titers with protection exceeding 70% against severe hospitalization across immunocompetent cohorts during primary 120-day observation windows. A recent study published in Nature Medicine has found that the recombinant shingles vaccine (Shingrix) may reduce the burden of cardiovascular disease by 9% compared to the older live vaccine (Zostavax). ## Understanding the Study The study, which analyzed data from over 72,000 adults aged 60 and over, found that those who received Shingrix had a 9% lower cardiovascular disease burden over a 7-year period. The researchers compared the cardiovascular outcomes of individuals who received Shingrix with those who received Zostavax before its discontinuation in the United States in 2020. They also noted that this was an observational study, which means they cannot prove cause and effect. More research is needed to understand how shingles vaccination may affect cardiovascular disease risk. ## Why Might the Recombinant Shingles Vaccine Benefit Heart Health? The study examined the cardiovascular outcomes of adults who received the live shingles vaccine between April and September 2017, and those who received the recombinant vaccine between April and September 2018. The researchers found that those who received Shingrix had a 9% lower cardiovascular disease burden over 7 years compared with those who received Zostavax. ### Specific Reductions in Cardiovascular Events The researchers found specific reductions in cardiovascular events among those who had the Shingrix vaccine, including:

• 10% lower burden of coronary heart disease
• 12% lower burden of heart failure
• 12% lower burden of ischemic stroke in men, with no significant association in women
• 7% lower burden of atrial fibrillation (AFib) ## Possible Explanations for the Association Experts in the field have offered possible explanations for this association. Kevin Shah, MD, a board-certified cardiologist and Program Director of Heart Failure Outreach at MemorialCare Heart & Vascular Institute at Long Beach Medical Center, suggested that one possible explanation is inflammation. According to Dr. Shah, 'inflammation is a key player in the development of cardiovascular disease, and the Shingrix vaccine may be reducing inflammation in the body, which in turn is reducing the risk of cardiovascular disease.' ### Inflammation and Cardiovascular Disease Inflammation is a known risk factor for cardiovascular disease, and it is thought to play a key role in the development of atherosclerosis, the underlying cause of most cardiovascular events. The Shingrix vaccine contains a recombinant form of the varicella-zoster virus, which is the virus that causes shingles. The vaccine works by stimulating the immune system to produce antibodies against the virus, which in turn reduces the risk of shingles and may also reduce inflammation in the body. ### Other Possible Explanations Other possible explanations for the association between the Shingrix vaccine and reduced cardiovascular disease risk include the following:
• The Shingrix vaccine may be reducing the risk of cardiovascular disease by reducing the risk of shingles, which can cause inflammation and increase the risk of cardiovascular disease.
• The Shingrix vaccine may be reducing the risk of cardiovascular disease by reducing the risk of other age-related diseases, such as dementia and osteoporosis, which are also associated with inflammation.
• The Shingrix vaccine may be reducing the risk of cardiovascular disease by reducing the risk of other cardiovascular risk factors, such as high blood pressure and high cholesterol. The study found that the recombinant shingles vaccine (Shingrix) may reduce the burden of cardiovascular disease by 9% compared to the older live vaccine (Zostavax). The researchers found specific reductions in cardiovascular events among those who had the Shingrix vaccine, including a 10% lower burden of coronary heart disease, a 12% lower burden of heart failure, and a 12% lower burden of ischemic stroke in men. While the exact mechanisms underlying this association are not yet fully understood, experts in the field have offered possible explanations, including inflammation. Further research is needed to understand how shingles vaccination may affect cardiovascular disease risk.

Clinical Biomarker Tracking and Metabolic Energy Balance

Optimizing healthspan and physical performance requires objective biochemical tracking rather than relying on subjective energy sensations. Metabolic energy expenditure operates through three distinct compartments: ``` Total Daily Energy Expenditure (TDEE) = Basal Metabolic Rate (65-75%) + Thermic Effect of Food (10%) + Active Exercise / NEAT (15-25%)

| Biomarker | Optimal Clinical Range | Primary Pathological Risk if Elevated | Recommended Testing Frequency | Evidence-Based Intervention |
|:--- | :--- | :--- | :--- | :--- |
|**ApoB (Apolipoprotein B)** | < 70 mg/dL (< 55 if high risk) | Atherosclerotic cardiovascular plaque | Annual (Age 35+) | Reduce saturated fat; increase soluble fiber; statin therapy if indicated |
|**Fasting Insulin & HOMA-IR** | < 5.0 uIU/mL / HOMA-IR < 1.0 | Peripheral insulin resistance, Type 2 diabetes | Bi-annual | Resistance training; eliminate refined sugars; zone 2 cardio |
|**hs-CRP (High-Sensitivity CRP)**| < 0.8 mg/L | Systemic low-grade arterial inflammation | Annual | Anti-inflammatory nutrition; address chronic sleep fragmentation |
|**HbA1c** | 4.8% – 5.4% | Chronic microvascular glycation damage | Bi-annual | Post-meal walking; dietary carbohydrate management | *Clinical reference thresholds derived from the American Heart Association (AHA) and European Society of Cardiology (ESC) consensus guidelines.* ### Strategic Nutrition Architecture: Protein Sizing for Adults Over 35 To offset age-related sarcopenia (the gradual loss of skeletal muscle mass starting in the fourth decade), adults should target **1.6 to 2.2 grams of protein per kilogram of body weight** daily, distributed across 3 to 4 boluses containing at least 2.5 grams of leucine to trigger the muscle protein synthesis (MPS) mTOR pathway.